Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation
This article was originally published in The Tan Sheet
Executive Summary
Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.
You may also be interested in...
Star Scientific IND Blocks Supplement Marketing Options – FDA
An FDA warning letter deems Star Scientific’s CigRx and Anatabloc supplements unapproved drugs due to multiple issues, including claims. The firm’s approved IND study for the ingredient also prevents its use in supplements, the agency says.
FDA's Tobacco Center To Mull First Modified-Risk Claim Application
FDA will have a complex public health impact equation to balance as its Center for Tobacco Products faces its first application for "modified-risk" tobacco product claims
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.